Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
JHEP Rep
; 5(4): 100661, 2023 Apr.
Article
en En
| MEDLINE
| ID: mdl-36866389
ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; CK-18 M30, caspase-cleaved cytokeratin 18; ELF, enhanced liver fibrosis; FGF21, fibroblast growth factor 21; FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; MRI-PDFF, MRI-proton density fat fraction; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; P3NP, procollagen-3 N-terminal propeptide; PC3X, crosslinked ADAMTS-2-released N-terminal type III collagen propeptide; PGBF, pegbelfermin; PRO-C3, monomeric ADAMTS-2-released N-terminal type III collagen propeptide; SomaSignal; T2D, type 2 diabetes; TG, triglycerides; TIMP-1, tissue inhibitor of metalloproteinases type 1; fibroblast growth factor 21; liver fibrosis; non-alcoholic steatohepatitis; precirrhotic NASH; steatosis
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Idioma:
En
Revista:
JHEP Rep
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Países Bajos